<DOC>
	<DOCNO>NCT02943213</DOCNO>
	<brief_summary>Cycle Pharmaceuticals Ltd. ( Cycle ) develop oral tablet formulation Chlorpromazine Hydrochloride intend conduct bioequivalence trial demonstrate similarity RLD . The aim pilot study investigate intrasubject variability bioavailability Chlorpromazine Hydrochloride 25 mg sugar coat tablet . Cycle aim demonstrate Chlorpromazine Hydrochloride shallow dose response curve wide safety margin . This allow modification bioequivalence acceptance criterion future pivotal study reduce number participant require whilst still maintain assurance safety efficacy . Pilot Subjects ( n ) : 20 Periods : 2 ( 2xR ) Dosing : Single-dose Strength : 25 mg Test Product : N/A Reference : USL PHARMA Chlorpromazine Hydrochloride Analytes ( plasma ) : Chlorpromazine ; 7-Hydroxychlorpromazine Bioequivalence base 90 % CI ( Cmax , AUC ) : Standard ; 80.00 - 125.00 %</brief_summary>
	<brief_title>Assessment Intra-subject Variability Bioavailability Chlorpromazine Hydrochloride</brief_title>
	<detailed_description>This single-dose , open-label , two-period replicate pilot study orally administer chlorpromazine hydrochloride 25 mg ( sugar coat tablet ) conduct fasting condition least 16 healthy male female subject single study center . Up 20 eligible subject enrol study 16 evaluable subject complete study . Analytes measure Chlorpromazine 7-hydroxy-Chlorpromazine ( free ) stipulate FDA Guidance assessment bioequivalence Chlorpromazine .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Porphyrias</mesh_term>
	<mesh_term>Porphyria , Acute Intermittent</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Chlorpromazine</mesh_term>
	<criteria>1 . Healthy male female , 18 65 year ( inclusive ) signing informed consent . 2 . Body Mass Index ( BMI ) 18.5 30 kg/m2 ( inclusive ) . 3 . Body mass le 50 kg . 4 . Medical history , vital sign , physical examination , standard 12lead electrocardiogram ( ECG ) laboratory investigation must clinically acceptable within laboratory reference range relevant laboratory test , unless investigator considers deviation irrelevant purpose study . 5 . Nonsmokers . 6 . Females , : Not childbearing potential , e.g. , surgically sterilize , undergone hysterectomy , amenorrhea â‰¥ 12 month consider postmenopausal , Note : In postmenopausal woman , value serum pregnancy test may slightly increase . This test repeat confirm result . If increase indicative pregnancy , female include study . OR Of childbearing potential , follow condition meet : Negative pregnancy test If test positive , subject exclude study . In rare circumstance pregnancy discover subject receive IMP , every attempt must make follow term . Not lactate Abstaining sexual activity ( usual lifestyle subject ) must agree use accepted method contraception , agree continue method throughout study . Examples reliable method contraception include nonhormonal intrauterine device , barrier method combine additional contraceptive method . In study concomitant use hormonal contraceptive NOT allow . Other method , consider investigator reliable , accept . 7 . Written consent give participation study . 1 . Evidence psychiatric disorder , antagonistic personality , poor motivation , emotional intellectual problem likely limit validity consent participate study limit ability comply protocol requirement . 2 . Current alcohol use &gt; 21 unit alcohol per week male &gt; 14 unit alcohol per week female . 3 . Consumption 5 cup coffee ( equivalent amount caffeine ) per day . 4 . Regular exposure substance abuse ( alcohol ) within past year . 5 . Use medication , prescribe overthecounter herbal remedy , within 2 week first administration IMP except affect outcome study opinion investigator . In study concomitant use hormonal contraceptive NOT allow . 6 . Participation another study experimental drug , last administration previous IMP within 8 week ( within 10 elimination halflives chemical entity 2 elimination halflives antibody insulin ) , whichever long ) administration IMP study , discretion investigator . 7 . Treatment within previous 3 month first administration IMP drug welldefined potential adversely affect major organ system . 8 . A major illness 3 month commencement screening period . 9 . History hypersensitivity allergy IMP excipients related medication include phenothiazine antipsychotic antiemetic . 10 . History extrapyramidal symptom . 11 . History liver renal dysfunction , epilepsy , Parkinson 's disease , hypothyroidism , cardiac failure , phaeochromocytoma , myasthenia gravis , prostate hypertrophy . 12 . Familial history deep vein thrombosis . 13 . Hereditary problem galactose intolerance , Lapp lactase deficiency . 14 . History QT prolongation sign QT prolongation ECG . 15 . History bronchial asthma bronchospastic disease . 16 . History convulsion . 17 . History porphyria . 18 . Relevant history laboratory clinical finding indicative acute chronic disease , likely influence study outcome . 19 . Donation loss blood equal exceed 500 mL 8 week first administration IMP . 20 . Diagnosis hypotension make screening period . 21 . Diagnosis hypertension make screening period current diagnosis hypertension . 22 . Resting pulse &gt; 100 beat per minute &lt; 40 beat per minute screening period , either supine standing . 23 . Positive test HIV Hepatitis B Hepatitis C. 24 . Positive urine screen drug abuse . In case positive result urine screen drug abuse may repeat discretion investigator . 25 . Positive urine screen tobacco use . 26 . Female subject pregnant ( positive pregnancy test ) breastfeeding . 27 . Difficulty swallow . 28 . Any specific investigational product safety concern . 29 . Vulnerable subject , e.g. , person detention .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Chlorpromazine</keyword>
	<keyword>Hydrochloride</keyword>
	<keyword>Chlorpromazine Hydrochloride</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Variability</keyword>
	<keyword>Variable</keyword>
	<keyword>Absorption</keyword>
	<keyword>USL Pharma</keyword>
	<keyword>USL</keyword>
	<keyword>Healthy</keyword>
	<keyword>South Africa</keyword>
	<keyword>Cycle</keyword>
	<keyword>Anti-Psychotic</keyword>
</DOC>